Ogeda Private

Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com

Investors

Technology: Medical Devices
Headquarters: Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Funding Status: M&A
Founded Date: 1994
Last Funding Type: Series B
Investors Number: 5
Last Funding Date: 2015-10-02
Estimated Revenue: $1M to $10M
Employee Number: 11-50
Total Funding: $30 940 286
Industry: PharmTech
Investor Type: For Profit
Register and Claim Ownership